“The REMS Is Gone” Is Not “The Monitoring Is Gone”

A federal program ended. A label recommendation didn’t. What disappeared between those two sentences was the system that noticed when the blood draws stopped.

The following vignette is a fictional composite constructed for illustration. It does not describe any actual patient, clinician, clinic, or pharmacy.

A psychiatrist takes over a panel at a community mental health center. One of the inherited patients has been stable on clozapine for nine years. The chart tells a clean story until it doesn’t: monthly ANCs, on schedule, month after month — and then May 2025, and then nothing. No abnormal value. No documented decision. The last relevant note reads, in its entirety: “Clozapine REMS discontinued per FDA — monitoring no longer required.”

The new psychiatrist calls the pharmacy. The pharmacist is pleasant and unbothered: the registry is gone, they don’t verify anything anymore, the refills have been going out on time. The psychiatrist asks when the patient’s last ANC was drawn. The pharmacist says that’s not really their question now. And it isn’t.

Here is the thing to notice. Nobody in this story decided to stop monitoring this patient. Not the previous psychiatrist, who wrote a note about a federal program, not about a person. Not the pharmacist, whose workflow simply stopped asking. Not the patient, who was never told anything changed. A compliance system was switched off, and everyone downstream read the silence as a clinical decision.

“No longer required” was doing a lot of quiet work in that note. Required by whom? For what? The registry requirement ended. The label recommendation did not. The note collapsed the two, and the labs stopped.

“The REMS is eliminated” is a statement about a distribution program. It is not a statement about a patient.

REMS elimination is a regulatory status. ANC monitoring is a clinical act — one with an owner, a schedule, an order, a result, and a chart entry. In February and June of 2025, the status changed. The act did not become unnecessary; the federal mechanism that forced it into the dispensing workflow disappeared. The reasons for the act — a drug that causes severe neutropenia, a boxed warning that still says so, a prescribing information that still specifies when to check — stayed exactly where they were.

The sentence this article exists to defend is short:

That distinction — requirement versus recommendation, and who owns each — is the whole piece. Readers of this newsletter will recognize the shape. In “The Non-Compete Is Banned” Is Not Your Contract, we argued that “the non-compete is banned” is not the status of your contract, because a clause has a governing law and a headline is not it. The same move works here, one layer down: a monitoring practice has a source of authority. In 2024, the registry operationalized the schedule and made that source impossible to ignore. Today, the prescribing information carries the FDA recommendation with no registry enforcing it. Clinicians who never read past the headline are now practicing under a document they may not have opened since the registry made opening it unnecessary.

General coverage compressed the end of the Clozapine REMS into a single event — “FDA eliminates clozapine REMS” — and moved on. There were three events, in three different regulatory registers, and the differences matter.

February 24, 2025. FDA announced that it “does not expect” prescribers, pharmacies, and patients to participate in the Clozapine REMS, or to report absolute neutrophil count results before pharmacies dispense. Read that verb carefully. This was a non-enforcement posture toward a REMS that still legally existed. The program was alive; the agency had stopped expecting anyone to feed it. In the same breath, FDA said it still recommended that prescribers monitor ANC according to the frequencies in the prescribing information. The recommendation and the non-enforcement announcement arrived together, in the same statement — and only one of them was built for a headline.

June 13, 2025. The elimination became effective. The REMS — the entity that required enrollment of prescribers, pharmacies, and patients, and reporting of ANC results as a condition of dispensing — formally ceased to exist. This is the date the legal state actually changed. It is also the date the current prescribing information carries: the label was revised in June 2025, including the boxed warning and the dosage-and-administration sections that house the monitoring tables.

August 27, 2025. FDA issued the Drug Safety Communication describing the completed removal. For a reader who arrives at this story through the Drug Safety Communication, this is the date that looks like the event, because it is the date the press-friendly document appeared. It is the announcement of a thing that had been legally true for ten weeks and operationally true for six months.

Announcement, effective date, communication date. Regular readers will recognize this as the same discipline this newsletter applied to federal orders: the date something is said and the date something is are different facts, and coverage that merges them will eventually make you wrong about which regime you were under in a given month. A prescriber asking “what governed my monitoring obligations in April 2025?” gets a genuinely layered answer — a legally extant REMS the agency had publicly stopped enforcing, plus a labeling recommendation that never moved. That layering is invisible in every one-date version of this story.

Now the centerpiece, and the part worth reading slowly, because this is the document that governs after the registry is gone.

The current Clozaril prescribing information — revised June 2025, the post-elimination label — retains the boxed warning for severe neutropenia. It retains the instruction to obtain a baseline ANC before initiation, with initiation not recommended below 1500/μL (below 1000/μL for patients with Benign Ethnic Neutropenia, also called Duffy-null associated neutrophil count). Section 5.1 states plainly that clozapine has caused severe neutropenia associated with serious and potentially fatal infections, directs clinicians to regularly monitor ANC throughout treatment, and notes: “The risk of severe neutropenia appears greatest during the first 18 weeks.”

And Section 2.3 still contains the monitoring schedule. The cadence survived the REMS intact: set the September 2024 label beside the June 2025 label, and the frequencies for a normal-range patient are identical — weekly through month 6, every two weeks through month 12, then monthly. What changed is the verb. The 2024 boxed warning said patients must have regular ANC monitoring, under a dosage section titled “Required Laboratory Testing”; the 2025 label carries the same schedule as a recommended frequency of ANC testing. The numbers persisted while the grammar moved from command to recommendation — the label-level shift, visible in a single word. Reproduced from Table 1 of the current prescribing information (for patients without BEN; the label’s Table 2 gives parallel recommendations for patients with BEN):

Set the August 2025 Drug Safety Communication next to that table. FDA, in the same document that announced the REMS removal, wrote that prescribers “should continue to monitor patients’ ANC” according to the frequencies in the prescribing information, that ANC monitoring can identify neutropenia early enough for timely intervention, and that the neutropenia risk itself remains. Even the patient-facing Medication Guide — issued June 2025, part of the same labeling FDA now says is sufficient to manage the risk — tells patients their provider will do blood tests weekly for the first six months, after which the provider will determine the frequency. The document that replaced the registry as the risk-management instrument still promises the patient a monitoring relationship — and it still names the clinician who will perform it. What it no longer contains is the external system that checked whether the monitoring occurred before dispensing continued.

One precision worth being pedantic about, because it is where careless versions of this article would overclaim: the frequencies in Table 1 are labeled recommended. FDA says prescribers should follow them. This is not the pre-2025 world with the enforcement removed; it is a genuinely different structure. Before June 2025 there were three layers — REMS requirements, labeling recommendations, clinical judgment. After June 2025 there are two. The article’s argument is not “monitoring is still required.” It is that the layer that vanished was never the layer that made monitoring clinically necessary — and that a schedule departing from the recommended frequencies now has to stand on the prescriber’s clinical reasoning rather than on anything the REMS required or validated. Under the REMS, a monitoring schedule arrived with external scaffolding — enrollment, submissions, an authorization step. Today, whatever schedule a patient is on is a schedule someone chose — or failed to choose. “The pharmacy dispensed it” and “my monitoring plan was clinically sound” used to be nearly the same sentence. They are now entirely different sentences, and only one of them will be of any interest to anyone reviewing the chart.

June 13 removed the federal mechanism that verified the act. It did not establish that the act was unnecessary.

It is tempting to say the burden “shifted” to the prescriber, and early drafts of this article said so. That framing is wrong in an instructive way.

The prescriber’s clinical obligation did not move on June 13, 2025, because it was always there. What the REMS added, and what elimination removed, was an external architecture that made certain omissions operationally difficult: enrollment, ANC submission, a pharmacy authorization step tied to monitoring status. Under that architecture, silently falling off monitoring was much harder, because the REMS repeatedly forced the absence of current monitoring information back into the dispensing workflow.

The responsibility wasn’t newly created. The backstop disappeared.

That is the precise second-order point, and it is why the vignette’s chart looks the way it does. The old system repeatedly made monitoring status visible at the point of dispensing. The new system permits clozapine dispensing to continue without REMS verification while the monitoring question goes not answered but unasked. The failure mode changed from “the pharmacy won’t release the drug” — loud, immediate, self-correcting — to “the labs quietly stop” — silent, cumulative, and discovered later, if at all, by whoever inherits the chart.

None of this is an argument that elimination was wrong. The access case was real: the REMS was a documented barrier to a drug that is chronically underused for treatment-resistant schizophrenia, and FDA concluded the labeling alone sustains a favorable benefit-risk profile. Burden was genuinely removed, and some of it was burden worth removing. The point is narrower and more useful: what was removed was compliance infrastructure, and what remains is clinical responsibility — and celebrating the first while assuming it took the second with it is precisely the conflation this series exists to catch.

It is also worth saying that June 13 did not, by itself, establish a new clinical standard of care. The federal dispensing requirement changed on that date. That does not mean every clinical, institutional, payer, or professional expectation changed with it. Institutional, payer, and pharmacy policies may impose requirements beyond the federal framework; the label’s recommendations stand. A prescriber whose entire post-REMS protocol is “the REMS is gone” is not standing on a new standard. They are standing on the absence of an old mechanism.

The observations above sort into four domains — the same four the companion worksheet uses, so the audit and the article share one skeleton.

Protocol. What does your clinic’s written clozapine process say today? If it references the registry, certification, or REMS reporting, it describes a system that ceased to exist in June 2025 — which means your actual governing process is unwritten. The replacement should name its governing source: the current prescribing information, by section.

Monitoring. For each clozapine patient: who orders the ANC, on what schedule, and where does the result land? A standing lab order aligned to the label’s frequencies — or to a documented alternative — with results routed to a person rather than a defunct portal.

Decision. For each patient, can you point to the chart entry where the current monitoring schedule was decided — dated, owned, reasoned — rather than inherited from a defunct program or assumed from silence? If the schedule departs from the label’s recommended frequencies, the reasoning carries the entire weight, because no external system is co-signing it anymore.

Communication. A pharmacy may continue to request ANC information or may dispense without it; either way, the pharmacy’s workflow is not the prescriber’s monitoring plan, so confirm the two actually align. And does the patient know what changed and what didn’t? Their Medication Guide changed in June 2025. It still tells them to expect blood tests. Someone should tell them why the tests continue when the registry that used to demand them is gone — or why, if their schedule changed, that was a decision someone made about them, with them.

Does your clinic’s clozapine protocol, as written today, reference a registry that no longer exists — and if it does, what document actually governs your monitoring practice in its place?

For each clozapine patient on your panel, can you point to the chart entry where the current ANC schedule was decided, rather than inherited or assumed?

If a patient’s monitoring schedule differs from the frequencies recommended in the current prescribing information, can you point to the documented clinical reasoning for that departure — knowing it now stands on that reasoning rather than on anything a program required or validated?

What does your patient believe changed in 2025 — and who told them?

A companion worksheet accompanies this issue: the four domains above (Protocol / Monitoring / Decision / Communication) with a Present / Absent / Unknown decision key per element, and a recap page restating the three dates and the thesis.

Each source below was opened and reviewed against the claims it supports. “Not used” notes are retained as the audit trail.

FDA, “Information on Clozapine” (fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/information-clozapine) — Used. February 24, 2025 announcement language (“does not expect” participation; ANC monitoring per prescribing information still recommended). Reviewed 2026-08-25.

FDA Drug Safety Communication, “FDA Removes Risk Evaluation and Mitigation Strategies (REMS) Program for the Antipsychotic Drug Clozapine,” dated August 27, 2025 (https://www.fda.gov/drugs/drug-safety-communications/fda-removes-risk-evaluation-and-mitigation-strategy-rems-program-antipsychotic-drug-clozapine and PDF at fda.gov/media/188418/download) — Used. June 13, 2025 effective date; description of removed REMS requirements (enrollment, ANC reporting before dispensing); “should continue to monitor patients’ ANC” per PI frequencies; labeling deemed sufficient to mitigate risk. Reviewed 2026-08-25.

Clozaril (clozapine) prescribing information, revised 6/2025 (accessdata.fda.gov/drugsatfda_docs/label/2025/019758s107lbl.pdf, Reference ID 5608164) — Used. Boxed warning; baseline ANC thresholds (1500/μL; 1000/μL BEN); Table 1 recommended frequencies and dosage modifications; Section 5.1 “regularly monitor ANC” and first-18-weeks language; Medication Guide (issued 06/2025) blood-test language. Recent Major Changes block confirms Boxed Warning and Section 2 revised 6/2025 (post-elimination revision). Reviewed 2026-08-25. Note: this is the Clozaril (NDA 019758) label; generic clozapine labels were not separately reviewed.

Clozaril (clozapine) prescribing information, revised 09/2024 (accessdata.fda.gov/drugsatfda_docs/label/2024/019758s104lbl.pdf, Reference ID 5445639) — Used. Pre-elimination comparator. Table 2 general-population frequencies (weekly ×6 months, every 2 weeks ×6 months, monthly thereafter — cadence identical to current label); boxed-warning “must have regular ANC monitoring” and Section 2.1 “Required Laboratory Testing” title for the required→recommended contrast; Section 5.2 Clozapine REMS Program requirements (prescriber/pharmacy certification, patient enrollment). Reviewed 2026-08-25.

November 19, 2024 Joint Advisory Committee meeting (DSaRM/Psychopharmacologic Drugs) — Not used. The evidentiary basis for elimination is outside this article’s scope; referenced only as background in the DSC. Not independently opened.

Psychiatric Times, Pharmacy Times coverage of the elimination — Used narrowly: basis for the characterization of how secondary coverage framed the elimination (“general coverage compressed” the three dates), and nothing else. No regulatory or clinical claim is sourced to these; per tier policy, all such claims rest on FDA documents and the labels directly.

ASCP statement on REMS elimination — Opened, not used. The 18-week risk-concentration claim is sourced to the current PI (Section 5.1) rather than the society statement.

S&PAA / AAPP “A New Era in Clozapine Management” educational initiative — Opened, not used. Professional-society response noted for awareness; no claims in this article rest on it.

Educational Disclaimer: The Psychiatric Record provides general educational information for psychiatric and mental-health professionals. Content does not constitute medical, legal, regulatory, compliance, billing, or other professional advice; does not establish a standard of care; and is not a substitute for independent professional judgment. Requirements and appropriate practices may vary by jurisdiction and circumstance. Verify current authoritative sources.

This article discusses the regulatory status and labeling of a specific prescription medication; it is commentary on documentation, systems, and regulatory structure, not prescribing guidance. Monitoring and treatment decisions for any individual patient rest with the treating clinician, informed by the current FDA-approved prescribing information and the patient’s clinical circumstances. Nothing here recommends any particular monitoring schedule for any patient.